San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process.
As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial pancreas. ViaCyte also just received FDA acceptance of its IND for its phase 1/2 clinical trial protocol for the artificial pancreas, aimed at patients with juvenile diabetes.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This news followed right on the heels of ViaCyte’s announcement earlier this month that it secured $5.4 million in Series C funding.
However, an August 21 regulatory filing indicates the company just raised $15 million. So which is it? Waiting for a call back from ViaCyte CEO Paul Laikind to confirm, but things are definitely clicking for this interesting startup. Stay tuned.
The artificial pancreas is actually pretty cool technology. Read about it here, or watch the company’s video above.
